Our observation of efficient internalization and targeting of LCN2 using siRNA-LCN2-loaded Herceptin-functionalized liposomes builds on these prior studies by evaluating promising innovative therapeutic avenues to inhibit the biological role of LCN2 in breast tumors. This evidence concerns the gene LCN2 and breast neoplasm.